신증후군 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The total market size of nephrotic syndrome in the 7MM was approximately USD 400 million in 2025. It is expected to grow at a significant CAGR, reaching a notable value by the end of 2036.
• DelveInsight's analyst projects that among the total Nephrotic Syndrome diagnosed prevalent cases in 7MM approximately 34% of cases were from the US.
• The total diagnosed prevalent cases of nephrotic syndrome in the 7MM were ~800,000 in 2025. These cases are expected to increase during the forecast period (2026-2036).
• In 2025, the US contributed nearly USD 200 million out of the 7MM market. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2022-2036).
• The total Nephrotic Syndrome Market Size is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, inaxaplin, GAZYVA/GAZYVARO (obinutuzumab), apecotrep (BI 764198), and others.
• The leading Nephrotic Syndrome Companies such as Vertex Pharmaceuticals, Roche, Boehringer Ingelheim, and others.

Key Factors Driving Nephrotic Syndrome Market

Nephrotic Syndrome Rising Prevalence

In 2025, the 7MM recorded approximately 800,000 diagnosed prevalent cases of Nephrotic Syndrome, with the US contributing about 34%. Increasing awareness, improved diagnostics, and rising chronic kidney disease prevalence are driving the growth in diagnosed cases, which are expected to rise further through the forecast period.

Nephrotic Syndrome Market Dynamics

The current treatment landscape includes corticosteroids, calcineurin inhibitors, ACE inhibitors/ARBs, and immunosuppressants, generating nearly USD 400 million in 2025. Market expansion is being propelled by the growing adoption of innovative therapies and the development of next-generation targeted treatments, which aim to improve patient outcomes and address unmet clinical needs.

Nephrotic Syndrome Emerging Therapies

Promising therapies in development include inaxaplin (Vertex Pharmaceuticals), GAZYVA/GAZYVARO (obinutuzumab) (Roche), apecotrep (BI 764198) (Boehringer Ingelheim), and others. These therapies focus on immune modulation, anti-fibrotic mechanisms, and targeted antibody approaches to better manage proteinuria and renal inflammation.

Nephrotic Syndrome Clinical Trials and Competitive Landscape

Key companies driving the Nephrotic Syndrome pipeline include Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen, Cerium Pharmaceuticals, Otsuka Pharmaceutical, Visterra, Ionis Pharmaceuticals, Kezar Life Sciences, Alpine Immune Sciences, Dimerix Bioscience, Advanz Pharma, Apellis Pharmaceuticals, Vera Therapeutics, and AstraZeneca. Recent FDA approvals and expanded indications, such as Enbumyst (bumetanide nasal spray) and Furoscix (furosemide injection), are enhancing treatment options and signaling robust growth potential for the Nephrotic Syndrome market.

DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Nephrotic Syndrome Treatment Market Report provides current treatment practices, emerging drugs, Nephrotic Syndrome market share of individual therapies, and current and forecasted 7MM Nephrotic Syndrome market size from 2022 to 2036. The report also covers current Nephrotic Syndrome treatment market practices/algorithms and Nephrotic Syndrome unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

Nephrotic Syndrome Treatment Market

Nephrotic Syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications of Nephrotic Syndrome. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications of Nephrotic Syndrome such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.

From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.

Nephrotic Syndrome Diagnosis

The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.

Nephrotic Syndrome Treatment

The Nephrotic Syndrome treatment involves addressing the fundamental cause and implementing measures to mitigate elevated blood pressure, elevated cholesterol levels, edema, and infection susceptibility. Therapeutic interventions typically comprise medications and dietary modifications. Certain antihypertensive Nephrotic Syndrome Drugs, specifically ACE inhibitors and ARBs, exhibit the potential to decelerate kidney diseases associated with nephrotic syndrome.

Nephrotic Syndrome Epidemiology

As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Nephrotic Syndrome Diagnosed Prevalent Cases and Nephrotic Syndrome Type-specific Diagnosed Prevalent Cases, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2022 to 2036.

• The total diagnosed prevalent cases of nephrotic syndrome in the 7MM were ~800,000 in 2025. These cases are expected to increase during the forecast period (2026-2036).
• Among EU4 and the UK, the highest diagnosed prevalent cases of nephrotic syndrome were recorded in Germany (~97,000) followed by the UK (90,000), in 2025. On the other hand, Spain accounted for the least cases, approximately 50,000 in 2025.
• According to DelveInsight's analysts, there were ~150,000 diagnosed prevalent cases of nephrotic syndrome in Japan in 2025, and this number is expected to change by 2036.

Recent Developmental Activities in the Nephrotic Syndrome Market

• In February 2026, Roche reported positive Phase III results from the MAJESTY trial, the first global Phase III study evaluating GAZYVA (obinutuzumab) in patients with primary membranous nephropathy.
• In January 2026, Boehringer Ingelheim reported results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor, in patients with FSGS. The study demonstrated that the 20 mg dose of apecotrep reduced proteinuria by 40% compared with placebo.
• In September 2025, Aptar Pharma announced that its Unidose Liquid System has been selected as the delivery platform for Enbumyst (Bumetanide Nasal Spray) 0.5mg, recently approved by the FDA. Developed by Corstasis Therapeutics, Enbumyst is the first intranasal loop diuretic approved for the treatment of edema associated with congestive heart failure, liver and kidney diseases, including nephrotic syndrome, in adults.
• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.
• In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024.
• In January 2025- Hoffmann-La Roche- This open-label, randomized multicenter study aims to evaluate the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab in comparison to mycophenolate mofetil (MMF) in children and young adults (aged 2 to 25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

Nephrotic Syndrome Drugs Market Chapters

The drug chapter segment of the Nephrotic Syndrome drugs market report encloses a detailed analysis of Nephrotic Syndrome marketed drugs and late-stage (Phase III and Phase II) Nephrotic Syndrome pipeline drugs analysis. It also understands Nephrotic Syndrome clinical trials details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest Nephrotic Syndrome news and press releases.

Nephrotic Syndrome Emerging Drugs

• Inaxaplin (VX-147): Vertex Pharmaceuticals

Inaxaplin, formerly known as VX-147, is an oral, small molecule apolipoprotein L1 (APOL1) inhibitor being developed by Vertex Pharmaceuticals to treat APOL1-mediated FSGS and other proteinuric kidney diseases. VX-147 is the first investigational treatment targeting the underlying cause of APOL1-mediated kidney disease (AMKD).

In September 2025, Vertex Pharmaceuticals reported the completion of enrollment in the IA cohort of the AMPLITUDE global Phase II/III clinical trial, evaluating Inaxaplin for its impact on kidney function and proteinuria in patients with AMKD.

In June 2022, the US FDA granted inaxaplin (VX-147) a Breakthrough Therapy Designation (BTD) for APOL1-mediated FSGS, and the European EMA granted inaxaplin Priority Medicines (PRIME) designation for AMKD. Additionally, inaxaplin is the first investigational therapy to treat the underlying cause of AMKD.

• Apecotrep (BI 764198): Boehringer Ingelheim

Apecotrep (BI 764198) is an oral inhibitor of TRPC6 (transient receptor potential cation channel subfamily C6) being developed by Boehringer Ingelheim for the treatment of FSGS. The therapy has been granted orphan drug designation (ODD) by both the European Medicines Agency (EMA) and Japan's Ministry of Health, Labour and Welfare (MHLW).

In January 2026, Boehringer Ingelheim reported results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor, in patients with FSGS. The study demonstrated that the 20 mg dose of apecotrep reduced proteinuria by 40% compared with placebo.

• GAZYVA/GAZYVARO (obinutuzumab): Roche

GAZYVA/GAZYVARO (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells and it is also approved active lupus nephritis.

In February 2026, Roche reported positive Phase III results from the MAJESTY trial, the first global Phase III study evaluating GAZYVA (obinutuzumab) in patients with primary membranous nephropathy.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications of Nephrotic Syndrome. The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications of nephrotic syndrome.

Currently, there are no authorized therapies specifically designed for treating nephrotic syndrome, and the predominant Nephrotic Syndrome treatment strategies often involve off-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

Progress in the Nephrotic Syndrome treatment has transformed patient care, integrating lifestyle modifications, medications, and procedures. Emerging therapies, including monoclonal antibodies and antagonists targeting APRIL and BAFF, among others, hold the potential for improving patient outcomes. Continuous research and ongoing Nephrotic Syndrome clinical trials are shaping a promising future for nephrotic syndrome treatment, providing optimism for a world with decreased morbidity and mortality.

• The total market size of nephrotic syndrome in the 7MM was approximately USD 400 million in 2025. It is expected to grow at a significant CAGR, reaching a notable value by the end of 2036.
• In 2025, the US contributed nearly USD 200 million out of the 7MM market. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2022-2036). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies.
• According to DelveInsight's analysts, the total EU4 and the UK market size of nephrotic syndrome was found to be ~USD 140 million in 2025, which is further expected to increase in the forecast period (2026-2036).
• The market size for nephrotic syndrome in Japan was approximately USD 65 million, and it is anticipated to rise by 2036.

Nephrotic Syndrome Drugs Uptake

This section focuses on the uptake rate of potential Nephrotic Syndrome drugs expected to launch in the market during 2022-2036. For example, Atacicept in the US is expected to be launched by 2027.

Nephrotic Syndrome Pipeline Development Activities

The Nephrotic Syndrome pipeline segment provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stages. It also analyzes Nephrotic Syndrome Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Nephrotic Syndrome pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for Nephrotic Syndrome emerging therapies.

KOL Views

To keep up with current Nephrotic Syndrome Therapeutics Market Trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on evolving Nephrotic Syndrome Treatment Market Landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston Children's Hospital, Ohio State University, Montefiore Medical Center, Hannover Medical School, Hannover, Hopital Robert-Debre, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundacion Jimenez Diaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Nephrotic Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Nephrotic Syndrome unmet needs.

Nephrotic Syndrome Therapeutics Market: Qualitative Analysis

We perform Qualitative and Nephrotic Syndrome Therapeutics Market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Nephrotic Syndrome Treatment Market Landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Nephrotic Syndrome Therapeutics Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The Nephrotic Syndrome therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Nephrotic Syndrome Therapeutics Market Report Scope

• The Nephrotic Syndrome therapeutics market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the Nephrotic Syndrome epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and Nephrotic Syndrome emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Nephrotic Syndrome treatment market landscape.
• A detailed review of the Nephrotic Syndrome Therapeutics Market, historical and forecasted Nephrotic Syndrome drugs market size, Nephrotic Syndrome market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The patient-based Nephrotic Syndrome Market Forecasting report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Nephrotic Syndrome Drugs Market.

Nephrotic Syndrome Drugs Market Report Insights

• Patient-based Nephrotic Syndrome Market Forecasting
• Therapeutic Approaches
• Nephrotic Syndrome Pipeline Analysis
• Nephrotic Syndrome Drugs Market Size
• Nephrotic Syndrome Drugs Market Trends
• Existing and Future Nephrotic Syndrome Drugs Market Opportunity

Nephrotic Syndrome Drugs Market Report Key Strengths

• 11 years Nephrotic Syndrome Market Forecast
• The 7MM Coverage
• Nephrotic Syndrome Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Nephrotic Syndrome Drugs Uptake
• Key Nephrotic Syndrome Market Forecast Assumptions

Nephrotic Syndrome Treatment Market Report Assessment

• Current Nephrotic Syndrome Treatment Market Practices
• Nephrotic Syndrome Unmet Needs
• Nephrotic Syndrome Pipeline Product Profiles
• Nephrotic Syndrome Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Nephrotic Syndrome Treatment Market Insights

• What was the Nephrotic Syndrome market size, the Nephrotic Syndrome treatment market size by therapies, and the Nephrotic Syndrome market share (%) distribution in 2022, and how would it all look in 2036? What are the contributing factors for this growth?
• What unmet needs are associated with the current Nephrotic Syndrome treatment market?
• What are the patents of Nephrotic Syndrome emerging therapies?
• Which drug is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the Nephrotic Syndrome market drivers, barriers, and future opportunities affect the Nephrotic Syndrome market dynamics and subsequent analysis of the associated trends?

Nephrotic Syndrome Epidemiology Insights

• What are the disease risks, burdens, and Nephrotic Syndrome unmet needs? What will be the growth opportunities across the 7MM concerning the Nephrotic Syndrome patient population?
• What is the historical and forecasted Nephrotic Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Nephrotic Syndrome and why?
• What factors are affecting the diagnosis of the indication?

Current Nephrotic Syndrome Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Nephrotic Syndrome? What are the current guidelines for treating Nephrotic Syndrome in the US and Europe?
• How many companies are developing therapies for treating Nephrotic Syndrome?
• How many emerging therapies are in the mid-stage and late stage of development for treating Nephrotic Syndrome?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the Nephrotic Syndrome Emerging Therapies?
• Patient acceptability in terms of preferred Nephrotic Syndrome Treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted Nephrotic Syndrome Drugs Market?

Reasons to Buy:

• The patient-based Nephrotic Syndrome Market Forecasting report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Nephrotic Syndrome Drugs Market.
• Insights on patient burden/disease Nephrotic Syndrome Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Nephrotic Syndrome Therapeutics Market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Nephrotic Syndrome Companies in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the Nephrotic Syndrome unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Nephrotic Syndrome Market Overview at a Glance

• 3.1. Nephrotic Syndrome Market Share (%) Distribution by Therapies in 2022
• 3.2. Nephrotic Syndrome Market Share (%) Distribution by Therapies in 2036

4. Epidemiology and Market Methodology of Nephrotic Syndrome

5. Executive Summary of Nephrotic Syndrome

6. Key Events

7. Nephrotic Syndrome: Disease Background and Overview

• 7.1. Introduction
• 7.2. Etiology
• 7.3. Clinical Manifestation
• 7.4. Complications
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm
• 7.7. Management and Treatment
  • 7.7.1. Treatment Algorithm
• 7.8. Guidelines
  • 7.8.1. Diagnosis and Management of Nephrotic Syndrome in Adults: American Family Physician (2016)
  • 7.8.2. International Pediatric Nephrology Association (IPNA) Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-resistant Nephrotic Syndrome (2022)
  • 7.8.3. Clinical Practice Guidelines for Nephrotic Syndrome (2022)
  • 7.8.4. Management of Childhood Onset Nephrotic Syndrome: The American Academy of Pediatrics (AAP)
  • 7.8.5. Clinical Commissioning Policy: National Health Service (NHS)
  • 7.8.6. Evidence-Based Clinical Practice Guidelines for Nephrotic Syndrome (2014)
  • 7.8.7. International Society of Nephrology: Kidney Disease Improving Global Outcomes (KDIGO), 2012
  • 7.8.8. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. FSGS
  • 8.2.2. IgA Nephropathy
  • 8.2.3. Membranous Nephropathy
  • 8.2.4. Others
• 8.3. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
  • 8.4.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
  • 8.5.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan
  • 8.6.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. Key Competitors
• 10.2. LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. BENLYSTA (belimumab): GSK
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Clinical Development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
• 10.4. INVOKANA (Canagliflozin): Johnson & Johnson
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. FILSPARI (Sparsentan): Travere Therapeutics/CSL Vifor
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental Activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile
• 10.6. TARPEYO (budesonide): Calliditas Therapeutics AB
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Clinical Development
  • 10.6.5. Clinical Trials Information
  • 10.6.6. Safety and Efficacy
  • 10.6.7. Product Profile

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Inaxaplin (VX-147): Vertex Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. Atrasentan: Chinook Therapeutics/ Novartis
  • 11.3.1. Product Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. BI 764198: Boehringer Ingelheim
  • 11.4.1. Product Description
  • 11.4.2. Clinical Development
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Product Profile
  • 11.4.5. Analysts' Views
• 11.5. Obinutuzumab (RG7159, GA101): Hoffmann-La Roche/Biogen
  • 11.5.1. Product Description
  • 11.5.2. Other Development Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
  • 11.5.6. Product Profile
  • 11.5.7. Analysts' Views
• 11.6. SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Other Development Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile
  • 11.6.7. Analysts' Views
• 11.7. VIS649 (sibeprenlimab): Otsuka Pharmaceutical Development & Commercialization/Visterra
  • 11.7.1. Product Description
  • 11.7.2. Other Development Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trials Information
  • 11.7.5. Safety and Efficacy
  • 11.7.6. Product Profile
  • 11.7.7. Analysts' Views
• 11.8. ASO factor B (IONIS-FB-LRx, RG6299): Hoffmann-La Roche/Ionis Pharmaceuticals
  • 11.8.1. Product Description
  • 11.8.2. Other Development Activities
  • 11.8.3. Clinical Development
  • 11.8.4. Clinical Trials Information
  • 11.8.5. Safety and Efficacy
  • 11.8.6. Product Profile
  • 11.8.7. Analysts' Views
• 11.9. Ianalumab (VAY736): Novartis
  • 11.9.1. Product Description
  • 11.9.2. Clinical Development
  • 11.9.3. Clinical Trials Information
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Product Profile
  • 11.9.6. Analysts' Views
• 11.1. Zetomipzomib (KZR-616): Kezar Life Sciences
  • 11.10.1. Product Description
  • 11.10.2. Other Development Activities
  • 11.10.3. Clinical Development
  • 11.10.4. Clinical Trials Information
  • 11.10.5. Safety and Efficacy
  • 11.10.6. Product Profile
  • 11.10.7. Analysts' Views
• 11.11. Povetacicept (ALPN-303): Alpine Immune Sciences
  • 11.11.1. Product Description
  • 11.11.2. Other Development Activities
  • 11.11.3. Clinical Development
  • 11.11.4. Clinical Trials Information
  • 11.11.5. Safety and Efficacy
  • 11.11.6. Product Profile
  • 11.11.7. Analysts' Views
• 11.12. DMX-200: Dimerix Bioscience/Advanz Pharma
  • 11.12.1. Product Description
  • 11.12.2. Other Development Activities
  • 11.12.3. Clinical Development
  • 11.12.4. Clinical Trials Information
  • 11.12.5. Safety and Efficacy
  • 11.12.6. Product Profile
  • 11.12.7. Analyst Views
• 11.13. EMPAVELI (pegcetacoplan): Apellis Pharmaceuticals
  • 11.13.1. Product Description
  • 11.13.2. Other Developmental Activities
  • 11.13.3. Clinical Development
  • 11.13.4. Clinical Trials Information
  • 11.13.5. Safety and Efficacy
  • 11.13.6. Product Profile
  • 11.13.7. Analyst Views
• 11.14. LNP023 (iptacopan): Novartis Pharmaceuticals
  • 11.14.1. Product Description
  • 11.14.2. Other Developmental Activities
  • 11.14.3. Clinical Development
  • 11.14.4. Clinical Trials Information
  • 11.14.5. Safety and Efficacy
  • 11.14.6. Product Profile
  • 11.14.7. Analyst Views
• 11.15. Zigakibart (BION-1301): Chinook Therapeutics, Inc./Novartis
  • 11.15.1. Product Description
  • 11.15.2. Other Developmental Activities
  • 11.15.3. Clinical Development
  • 11.15.4. Clinical Trials Information
  • 11.15.5. Safety and Efficacy
  • 11.15.6. Product Profile
  • 11.15.7. Analyst Views
• 11.16. Atacicept: Vera Therapeutics, Inc.
  • 11.16.1. Product Description
  • 11.16.2. Other Developmental Activities
  • 11.16.3. Clinical Development
  • 11.16.4. Clinical Trials Information
  • 11.16.5. Safety and Efficacy
  • 11.16.6. Product Profile
  • 11.16.7. Analyst Views
• 11.17. Saphnelo (anifrolumab): AstraZeneca
  • 11.17.1. Product Description
  • 11.17.2. Clinical Development
  • 11.17.3. Clinical Trials Information
  • 11.17.4. Safety and Efficacy
  • 11.17.5. Product Profile
  • 11.17.6. Analyst Views
• 11.18. Felzartamab (MOR202): HI-Bio
  • 11.18.1. Product Description
  • 11.18.2. Other Developmental Activities
  • 11.18.3. Clinical Development
  • 11.18.4. Clinical Trials Information
  • 11.18.5. Safety and Efficacy
  • 11.18.6. Product Profile
  • 11.18.7. Analyst Views

12. Nephrotic Syndrome: Seven Major Market Analysis

• 12.1. Key Findings: Market
• 12.2. Key Market Forecast Assumptions
• 12.3. Conjoint Analysis
• 12.4. Market Outlook
• 12.5. Market Size of Nephrotic Syndrome in the 7MM
• 12.6. Market size of Nephrotic Syndrome by Therapies in the 7MM
• 12.7. Market Size of Nephrotic Syndrome in the United States
  • 12.7.1. Total Market Size of Nephrotic Syndrome
  • 12.7.2. Market Size of Nephrotic Syndrome by Therapies
• 12.8. Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.1. Total Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.2. Market Size of Nephrotic Syndrome by Therapies
• 12.9. Market Size of Nephrotic Syndrome in Japan
  • 12.9.1. Total Market Size of Nephrotic Syndrome in Japan
  • 12.9.2. Market Size of Nephrotic Syndrome by Therapies

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer